Soleno Therapeutics (NASDAQ:SLNO) is one of the 17 Biotech Stocks With More Than 50% Up.
On January 20, HC Wainwright’s Ram Selvaraju raised his price target on Soleno Therapeutics (NASDAQ:SLNO) from $110 to $120. He also reaffirmed his Buy rating on the stock, which, according to his forecasts, offers a revaluation potential of almost 211%. The analyst based his rating on the company’s impressive sales figures, which continue to beat estimates.
Likoper/Shutterstock.com
On January 20, Wells Fargo analyst Derek Archila maintained an Overweight rating on Soleno Therapeutics (NASDAQ:SLNO). He also raised the price target from $106 to $114, leading to a revised upside potential of 195%.
Archila highlighted Vykat Extended Release’s fourth-quarter earnings that beat expectations. Although new PSFs were insufficient, recent comments from management confirmed a target of approximately 250 new starts per quarter, excluding the effects of any seasonal factors. Given the company’s strong cash flow profile, the analyst believes the stock is currently undervalued.
Soleno Therapeutics (NASDAQ:SLNO) is a clinical-stage biopharmaceutical company developing novel therapies for rare diseases such as Prader-Willi syndrome. Its lead product is choline diazoxide extended-release tablets, VYKAT XR. The company began marketing VYKAT XR in April 2025, following FDA approval.
While we recognize SLNO’s potential as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that’s also benefiting significantly from Trump-era tariffs and the offshoring trend, check out our free report on best short-term AI stock.
READ NEXT: 15 Most Promising Mid-Cap Healthcare Stocks Under $50 and 11 Most Promising Small Cap Industrial Stocks Under $50.
Disclosure: None. This article was originally published in Internal jumpsuit.